

ESRR'26
April 16-19, 2026, Bergen, Norway

22nd European Symposium on
Radiopharmacy &
Radiochemistry

FINAL PROGRAMME





TABLE OF CONTENT

For more than 20 years, JPT Peptide Technologies has supported the global biomedical community with high-quality peptide solutions spanning early discovery to clinical research.

From our state-of-the-art facilities in Berlin, Germany, we manufacture custom peptides under an ISO 9001:2015-certified quality management system, delivering quality, reliability, and reproducibility at every stage of your project.

For the radiopharmacy and radiochemistry community, JPT provides tailored peptide solutions to support the development of targeting vectors, reference compounds, screening tools, and preclinical research materials.

Our capabilities include:

- Linear, cyclic, stapled, and modified peptides
- Peptide libraries for screening and optimization
- Site-specific functionalization to enable conjugation strategies
- Light and heavy labelled peptides for analytical and bioanalytical applications

We look forward to discussing how JPT can support your peptide needs at ESRR'26 in Bergen.



4	Welcome Address
5	Organisation
6	Exhibitors & Sponsors
8	Programme Overview
14	Social Programme
15	Poster Presentations
22	Exhibition Plan
24	Notes

WELCOME ADDRESS

Dear Colleagues and Friends,

It is our great pleasure to welcome you to Bergen to attend the European Symposium on Radiopharmacy and Radiochemistry! We are delighted to host the 22nd edition of ESRR in Norway and to gather colleagues from across Europe and beyond for scientific exchange, collaboration, and discussion within our rapidly evolving field.

Often referred to as the gateway to the Norwegian fjords, Bergen is a historic coastal city on the western coast of Norway and has long served as an important center for trade, culture, and science. Founded in the year 1070, the city was once the capital of Norway and an important hub of the Hanseatic League. Today, Bergen is Norway's second-largest city and home to the University of Bergen, Haukeland University Hospital and several internationally recognized research institutions. Surrounded by mountains and fjords, the city offers a unique combination of rich cultural heritage, vibrant academic life, and spectacular natural scenery. The historic Bryggen wharf, a UNESCO World Heritage site, stands as a reminder of Bergen's long international connections.

The congress venue, Grieghallen, is one of Norway's most prominent cultural and congress centers. Named after the famous Norwegian composer Edvard Grieg, who was born, lived and worked in Bergen, the venue has hosted major international conferences, concerts, and cultural events since its opening in 1978. Located in the heart of the city, Grieghallen provides a top-modern and inspiring setting for scientific exchange and interaction.

The local host institution, Haukeland University Hospital, is one of Scandinavia's largest university hospitals and a central part of the Western Norway Regional Health Authority. Closely integrated with the University of Bergen, the hospital is a major center for medical research, clinical innovation, and advanced patient care.

In addition to the scientific programme, we hope you will have the opportunity to explore Bergen's historic streets, scenic surroundings, and vibrant cultural life. We trust that the combination of high-level science, engaging discussions, and the special atmosphere of this coastal city will make this 22nd ESRR meeting both productive and enjoyable. Velkommen til Bergen!

Tom Christian Holm Adamsen
Ole Heine Kvernenes



Photo:
Visit Bergen / Willy Haraldsen - visitBergen.com

ORGANISATION

Scientific Programme Committee:

Chair: Peter Laverman (Netherlands)

Martin Behe (Switzerland)
Jessica Bridoux (Belgium)
Frederik Cleeren (Belgium)
Filippo Lodi (Italy)
Thomas Mindt (Austria)
Cécile Philippe (Austria)

Local Organising Committee:

Tom Christian Adamsen
Ole Heine Kvernenes

Organising Secretariat:

AV ESRR
c/o EANM Executive Office
Schmalzhofgasse 26
1060 Vienna, AUSTRIA
+43 1 890 44 27
esrr@esrr.info
<http://www.esrr.info>

Congress Venue:

Grieghallen
Edvard Griegs Plass 1
5015 Bergen, Norway
<https://www.grieghallen.no/en>

EXHIBITORS & SPONSORS

We would like to thank all exhibitors and sponsors of the ESRR'26 for their support!

	Antec Scientific
	BIOEMTECH
	Bruker BioSpin GmbH & Co. KG
	COMECER S.p.A.
	Cyclomedica
	Eichrom Technologies
	Elysia-Raytest
	GE Healthcare Limited, UK
	Hidex Oy
	IBA SA
	IRE ELIT

	Isotopia Molecular Imaging Ltd
	Jiangsu Huayi Radiopharmaceuticals Co., Ltd.
	JPT Peptide Technologies GmbH
	LabLogic Systems Limited
	Nucare Inc.
	Ridgeview Instruments AB
	RQS Alexander Ruffani
	Trasis
	Triskem International
	Von Gahlen

SCIENTIFIC PROGRAMME

Thursday, April 16, 2026

17:30	Opening Ceremony & Welcome
17:45-18:30	Welcome Lecture Chairpersons: Peter Laverman, Tom Christian Holm Adamsen <i>Roger Strand</i> (Bergen University, Norway): Medical/Research Ethics and the Societal Ethical Aspects of Emerging Sciences and Technology
18:30-19:00	Walk to Venue for Welcome Reception
19:00	Welcome Reception

Friday, April 17, 2026

08:30-10:05	Session I Chairpersons: Sophie Poty, Verena Pichler
08:30-09:15	Back-to-basics I: Small Proteins-Based Diagnostic and Therapeutic Agents: Where We are and Where We are Going <i>Thomas Ertveldt</i> (Vrije Universiteit Brussel, Belgium)
09:15-10:05	» OP01: Jessica Bridoux: Unlocking Enzyme-Powered Radiofluorination of Single-Domain Antibodies Using VyPAL2 » OP02: Annemarie Doze: Design, Synthesis and Evaluation of a Novel Fibroblast Activation Protein Inhibitor (FAPi)-Tracer Radiolabeled Using an Ultrafast Photoclick Reaction » OP03: Kim de Roode: Use of Highly Reactive Click-To-Release Components for Improved Click-Cleavable Radioimmunotherapy » OP04: Célia Fernandes: Overcoming Cetuximab Resistance in Colorectal Cancer Using an EGFR/ SHP2-Targeted Theranostic Antibody-Drug Conjugate
10:05-10:35	Coffee Break

10:35-12:20	Session II Chairpersons: Cécile Philippe, Ludovic Le Saux
10:35-11:20	Emerging techniques: radioactive cell sorting and beyond <i>Cécile Philippe</i> (MedUni Vienna, Austria)
11:20-12:20	» OP05: Jennifer Storch: Hexadentate Acyclic DACH-Based Chelators for [212/203Pb]Pb2+: Towards Potential Applications in Nuclear Medicine » OP06: Ward Storms: Development & Preclinical Evaluation Of [18F]ALF-/([213Bi]Bi-3p-C-NETA-FAP2286, a Perfect Match for Short-Lived PET Imaging and TAT. » OP07: Camille Van Laere: Preclinical Evaluation of a New Theranostic Pair for CAIX-Positive Tumours: [18F]AlF-NOTA-DPI-4452 and [161Tb]Tb-DOTA-DPI-4452 » OP08: Simona Mastroianni: Carboxylic- and Amide Donor-Functionalized Pyridine-N-trans-Substituted Cyclen-Based Chelators for Lead-203 and Lead-212 Theranostic Radiopharmaceuticals » OP09: Abir Dhimen: Overcoming Chelator Limitations in Theranostics: a New Nota-Derived Hybrid for Al-18F and 177Lu
12:20-13:45	Lunch Break
13:45-15:18	Session III Chairpersons: Daniëlle Vugts, Jessica Bridoux
13:45-14:30	Animal experiments: 3R's, organoids and beyond <i>Emma Laporte</i> (KU Leuven, Belgium)
14:30-15:18	» OP10: Sébastien Guillet: 211At-Metal Bonding in N-Heterocyclic Carbene Complexes: Exploring an Alternative Side of the Halogen Chemistry of Astatine » OP11: Ludovic Le Saux: In Vivo Preclinical Assessment of [11C]Onalespib as a PET Radiotracer for Hsp90 Imaging » OP12: Anna Pees: Oxygen-15 Labelling of Carboxylic Acids via Ester Hydrolysis with [15O]Water
15:18-15:42	Coffee Break

15:42-16:30 Session IV

Chairpersons: Martin Behe, Diana Wicks

- » **OP14:** *Aicha Nour Laouameria:*
Palladium-103 as a Theranostic Auger Electron Emitter: from Cyclotron Production to Preclinical Spect Evaluation in Murine Models
- » **OP15:** *Magda Piatkowska:*
Palladium-103 -Labeled PsmA Radiotracer for Auger Electron Therapy of Prostate Cancer Metastases
- » **OP16:** *Lorenzo Tei:*
Development of a ¹⁰³Pd-Bioconjugate for Auger-Targeted Radionuclide Therapy
- » **OP17:** *Thomas Scheiblaue:*
Towards Auger Electron Therapy by Targeting the Cancer Biomarker Nucleolin with A F3-Radiopeptide Analog

16:30-17:00 Poster pitches

Chairpersons: Frederik Cleeren

- » **PP01:** *Subhadeep Paul:*
Development of Radiolabeled Nir- Silicon Rhodamines as Bimodal Radio/Optical Agents for Theranostic Cancer Treatment
- » **PP02:** *Ahmad Kurniawan:*
Radiosynthesis and In Vitro Evaluation of [¹²⁵I]CC1, a PARP-Targeted Auger Electron Radionuclide Therapy Agent
- » **PP03:** *Frederik Sachse:*
Development of Novel Chelator-Based Small-Molecule Radioligands for Imaging PD-L1-Positive Tumors
- » **PP04:** *Alessia Savio:*
Development of ¹⁷⁷Lu-iPSMA-iGRP78 Heterodimer with enhanced Internalisation in Prostate Cancer Cells
- » **PP05:** *Elmar Diekstra:*
[¹²³I]iodobicalutamide, a Novel Androgen Receptor Radioligand for Targeted Radionuclide Therapy and SPECT Imaging.
- » **PP06:** *Rafał Walczak:*
Radiobioconjugates of Co-55 for Three Gamma Tomography
- » **PP07:** *Jingjing Yu:*
Design and Evaluation of a ⁶⁸Ga-Labeled Dimeric Cyclic Peptide as a Large-Volume Linker Strategy for Balancing Affinity and Retention in CXCR4-Targeted PET Imaging
- » **PP08:** *Barbara Janota:*
Radical Scavenging Strategies in the Synthesis of Ac-225-Based Radiopharmaceuticals: A Two-Stage Approach to Minimize Autoradiolysis and Enhance Clinical Stability
- » **PP09:** *Laurene Wagner:*
Synthesis and Radiolabelling of Estradiol- and Peptide-Based Ligands Targeting Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 for Breast Cancer Radiotheragnostics

Saturday, April 18, 2026

08:30-10:05 Session V

Chairpersons: Robin de Kruijff, Barbara Lugato

- 08:30-09:15 **Back-to-basics II: Basics of reactor production of radionuclides**
Robin de Kruijff (TU Delft, Reactor Institute, Netherlands)
- 09:15-10:05
 - » **OP18:** *Pavel Barta:*
¹⁶¹Tb-Labeled Antiangiogenic Monoclonal Antibody Ramucirumab as an Effective Tool for Therapy of VEGFR2-Positive Micrometastasis
 - » **OP19:** *Johannes Nikodemus Staudinger:*
Development of Ruthenium-Based Photosensitizers Isotopically Labeled with Ru-97/103 for Theranostic Applications and Combined PDT/Endoradiotherapy
 - » **OP20:** *Ahmad Kurniawan:*
Assessing Cancer Cell Delivery of [¹⁶¹Tb]Tb-DOTA-olaparib Using Liposome Encapsulation Strategies
 - » **OP21:** *Eliza Lambidis:*
Radiochemistry and Preclinical Imaging Workflow For Tracking ²²⁵Ac Daughter Emissions in a FAP-targeted Oncology Model

10:05-10:35 Coffee Break

10:35-12:20 Session VI

Chairpersons: Julie Bolcaen, Filippo Lodi

- 10:35-11:20 **Why radiobiology and cellular dosimetry matter for advancing targeted radionuclide therapy**
Julie Bolcaen (Paul Scherrer Institut PSI, Switzerland):
- 11:20-12:20
 - » **OP22:** *Naveen Kumar:*
Prostate Cancer Theranostics Using ¹⁷⁷Lu and ⁴⁷Sc-labeled Grpr Antagonists: Integrated Imaging and Targeted Radionuclide Therapy in Combination with Everolimus
 - » **OP23:** *Maxime Cheveau:*
A First ¹⁷⁷Lu/¹⁶¹Tb/²²⁵Ac Radioimmunoconjugate Comparative Therapy Study Enabled by the Use Of A Versatile Bifunctional PYTA Chelator.
 - » **OP24:** *Barbara Lugato:*
Chelators for the Development of Complexes Radiolabeled with Ruthenium-97/103: a New Theranostic Tool for Nuclear Imaging and Endoradiotherapy
 - » **OP25:** *Maximilian Anderla:*
Unlocking the Potential of Ruthenium Radioisotopes for Radiopharmaceutical Development

12:20-13:45 Lunch Break

13:45-15:30	Session VII
	Chairpersons: Jonathan Cotton, Philip Elsinga
13:45-14:30	Emerging techniques in C-11 and F-18 radiochemistry <i>Jonathan Cotton</i> (Werner Siemens Imaging Center, Germany)
14:30-15:30	» OP27: Shireen Jozi: Structure-Activity-Relationship Investigation Of Modifications at the C-terminus of [68Ga]Ga-LW02050 on the Effect of the in Vitro/Vivo GRPR-Targeting Capability » OP28: Fatemeh Radnia: Substitution of Lysine1 in [68ga]ga-z02176, a Bradykinin B1 Receptor-Targeting PET Tracer, with lys(me), lys(me)2 or lys(me)3 Significantly Reduces Kidney Uptake While Relatively Retaining the Tumor Uptake » OP29: Mattia Asti: Tuning the Pharmacokinetic Profile of Two 68Ga-labelled Nastorazepide Derivatives Targeting CCK2R Expressing Tumors. » OP30: Paulina Pazitkova: Evaluating Multi-Site Chelation Strategies in PSMA Ligands: Insights from PSMA-617 and PSMA I&T » OP31: Shireen Jozi: Synthesis and Evaluation of 68Ga-labeled [D-Phe6,Thz14]Bombesin(6-14) Derivatives for Detecting Gastrin-Releasing Peptide Receptor-Expressing Cancer with Positron Emission Tomography
15:30-16:00	Coffee Break
16:00-18:00	Session VIII: Pharmacopeia Corner and GMP session – clinical trials with radiopharmaceuticals
	Chairperson: Oliver Kiß
16:00-16:05	» Introduction of the session <i>Oliver Kiß</i> (Helmholtz-Zentrum Dresden-Rossendorf, Germany)
16:05-16:25	» Pharmacopoeia Update <i>Thijs Kroon</i> (Netherlands)
16:25-16:55	» Navigating the Bottlenecks in the Translation of Novel Radiopharmaceuticals <i>Margret Schottelius</i> (CHUV – Lausanne University Hospital, Switzerland)
16:55-17:25	» Clinical Trials in Nuclear Medicine: From Authorization to Execution <i>Felicitas Landau</i> (University Hospital Münster, Germany)
17:25-17:35	» AEA TWG-RPHR: Shaping the Future of Radiopharmaceutical Regulation Together <i>Clemens Decristoforo</i> (University Hospital Innsbruck, Austria)
17:35-18:00	» Pharmacopoeia Corner – Roundtable Discussion/Open Forum with Panelists <i>Marianne Patt</i> (University Hospital Augsburg, Germany), <i>Clemens Decristoforo</i> (University Hospital Innsbruck, Austria), <i>Felicitas Landau</i> (University Hospital Münster, Germany), <i>Margret Schottelius</i> (CHUV Lausanne, Switzerland)
20:00	Social Event supported by EANM

Sunday, April 19, 2026

08:30-10:05	Session IX
	Chairpersons: Margret Schottelius, Thomas Ertveldt
08:30-09:15	Back-to-basics III: Unveiling the Tumor Microenvironment through radiopharmaceuticals: beyond FAPI <i>Margret Schottelius</i> (CHUV – Lausanne University Hospital, Switzerland)
09:15-10:05	OP32: Martijn Moers: The Radiobiological Effects of FAP-targeted Radionuclide Therapy on Primary Cancer-Associated Fibroblasts OP33: Adrianna Bilinska: FAP Biology Determines the Diagnostic and Therapeutic Pharmacokinetics of Monomeric and Dimeric FAPI Radiopharmaceuticals OP34: Filipe Elvas: FAP PET/CT Imaging Using a Druglike 18F-FAPI in an Orthotopic Model of Pancreatic Adenocarcinoma OP35: Naveen Kumar: Theranostic Potential of DOTAGA.GLU2.(FAP)2 with Enhanced Tumor Retention: Insights Into Imaging Performance and Efficacy of Fractionated Monotherapy
10:05-10:35	Coffee Break
10:35-11:35	Session X: ESRR-EANM joint session - Radiopharmaceutical Education: Mapping Needs and Gaps
	Chairpersons: Peter Laverman, Filipe Elvas
	Panel members: » <i>Marko Kroselj</i> (Ljubljana, Slovenia) - Coordinator Radiopharmacy course ETH » <i>Robin de Kruijff</i> (TU Delft, Reactor Institute, Netherlands) - Project leader of 2 national educational grants in NL » <i>Daniëlle Vugts</i> (Amsterdam UMC, Netherlands) » <i>Oliver Kiß</i> (Helmholtz-Zentrum Dresden-Rossendorf, Germany) - involved in German educational activities
11:35-12:15	Closing / Award ceremony
	Chairperson: Thomas Mindt
12:15	Farewell Lunch

SOCIAL PROGRAMME

Thursday, April 16, 2026
19:00

Welcome Reception
Håkonshalle
Bergenhus 10, 5003 Bergen

Saturday, April 18, 2026
20:00

Social Event supported by EANM
Galleri Nygaten
Nygaten 7, 5017 Bergen

Sunday, April 19, 2026
12:15

Farewell Lunch
Congress Venue



POSTER PRESENTATIONS

PP01
Development of Radiolabeled NIR- Silicon Rhodamines as Bimodal Radio/Optical Agents for Theranostic Cancer Treatment
Subhadeep Paul, Germany

PP02
Radiosynthesis and In Vitro Evaluation of [125I]CC1, a PARP-Targeted Auger Electron Radionuclide Therapy Agent
Ahmad Kurniawan, Netherlands

PP03
Development of Novel Chelator-Based Small-Molecule Radioligands for Imaging PD-L1-positive Tumors
Frederik Sachse, Germany

PP04
Development of ¹⁷⁷Lu-iPSMA-iGRP78 Heterodimer with Enhanced Internalisation in prostate Cancer Cells
Alessia Savio, Italy

PP05
[123I]Iodobicalutamide, A Novel Androgen Receptor Radioligand for Targeted Radionuclide Therapy and SPECT Imaging.
Elmar Diekstra, Netherlands

PP06
Radiobioconjugates of Co-55 for Three Gamma Tomography
Rafał Walczak, Poland

PP07
Design and Evaluation of a ⁶⁸Ga-Labeled Dimeric Cyclic Peptide as a Large-Volume Linker Strategy for Balancing Affinity and Retention in CXCR4-Targeted PET Imaging
Jingjing Yu, China

PP08
Radical Scavenging Strategies in the Synthesis of Ac-225-Based Radiopharmaceuticals: A Two-Stage Approach to Minimize Autoradiolysis and Enhance Clinical Stability
Barbara Janota, Poland

PP09
Synthesis and Radiolabelling of Estradiol- and Peptide-Based Ligands Targeting Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 for Breast Cancer Radiotheragnostics
Laurene Wagner, Germany

PP10
A Rigorous Monte Carlo Simulation Framework for Actinium-225-PSMA-617 Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer
Ali Alshehri, Saudi Arabia

PP12
Improved Quality Control of [¹⁸F]FDG: Overcoming Matrix Effects with Advanced Column and Rinsing Strategies
Detlef Jensen, Netherlands

PP13
Product Quality Review of the [¹⁸F]FDG radiopharmaceutical
Marija Atanasova Lazareva, North Macedonia

PP14
Integrating Risk Assessment for Effective Process Control in Radiopharmaceutical Production Facility
Maja Chochevska, North Macedonia

PP15
Stereoselective Synthesis of ¹⁸F-Labeled Specialized Pro-Resolving Mediators
Åshild Sørskår, Norway

PP16
Synthesis and Preclinical Evaluation of Gallium-68 and Zirconium-89 Labeled Desferrioxamine-B Analogues for PET/CT Imaging of Infection.
Robin Maradan, Austria

PP17
Preclinical Target Validation of the Chemokine Receptor Type 2 Supporting Brain PET Tracer Development
Bieneke Janssen, Netherlands

PP18
[¹⁸F]Fluoroethylveliparib: A novel PET Radiotracer for PARP Imaging in Glioblastoma
Sreelakshmi Unnikrishnan, Netherlands

PP19
Comparison of Alpha-Synuclein Binding of Several PET-tracer Candidates by Molecular Docking and ¹⁸F-Labeling/Automation of Most Potent Molecule
Fernando Oviedo Garza, Netherlands

PP20
Development and Evaluation of Two [^{99m}Tc]TC Tricarboxylic Complexes Derived from Erlotinib for Molecular Imaging in Triple Negative Breast Cancer.
Maria Emilia Tejeria, Uruguay

PP21
Introducing Site-Specific N-terminal Modification and Radiolabeling of Nanobodies for Improved in Vivo Performance
Marie Velada Dugois, Netherlands

PP22
Evaluation of the Metabolic Response of Glioblastoma Spheroids to [⁶⁴Cu]CuCl₂
Filipa Mendes, Portugal

PP23
Radiosynthesis of an ¹⁸F-Labelled Covalent Tracer for PET Imaging of Mutant Isocitrate Dehydrogenase 1
Dana Zappaterra, Germany

PP24
Optimizing [¹⁸F]F-JK-PSMA-7 Production: an Spe-Based Purification Strategy
Chiara Favaretto, Italy

PP25
A Simple Solid-Phase Approach for the Synthesis of DOTA-conjugated Alpha-Ketoamide-Based Fibroblast Activation Protein-Targeted Ligands
Shireen Jozi, Canada

PP26
Comparative PET/CT Imaging of Bacterial Infection: Ferrioxamine E vs. Its Derivative Ferrioxamine 2-5
Kateřina Dvořáková Bendová, Czech Republic

PP27
Synthesis and Optimization of [¹²³I]CC1 as Tracer for PARP Targeting
Sreelakshmi Unnikrishnan, Netherlands

PP28
PSMA-Radiotheranostics Carrying a DNA Intercalator to Unlock the Potential of Auger Electron Therapy in Prostate Cancer
Antonio Paulo, Portugal

PP29
Investigation of Sulfur and Selenium-Based Ligands for Complexation Of Metallic Astatine-211
Camille Custodio, France

PP31
Comparison of the Properties of Diastereoisomers of [¹⁷⁷Lu]Lu-PSMA-D4 (L-Trp vs D-Trp) in Preclinical Studies
Michał Wrzecionek, Poland

PP32
Preclinical Assessment of [⁶⁴Cu]Cu-NODAGA-PSMA-I&T as a Theranostic Agent for Prostate Cancer
Diana Rodrigues, Portugal

PP33
Radiolabeling HBED with Titanium-45: Stability Insights from In Vitro and Computational Studies
Eduard Pogorilyy, Norway

PP34
Radiobiological Response of Androgen Receptor (ar) Suppression in Combination with Alpha Therapy
Fawaz Alqahtani, Saudi Arabia

PP35
Development and Characterization of Technetium-99m Labeled Holmium Microspheres for Scout Dose Imaging in Radioembolization Treatment Planning
Milou Boswinkel, Netherlands

PP36
⁶⁸Ga-Tracers for Imaging of the Hepatobiliary Function
Julia Greiser, Germany

PP37
In-vitro Characterization of a Photoclick-Derived PSMA Ligand using Human and Murine Prostate Cancer Models
Meryl Maria Vilangattil, Netherlands

PP38
Aryl and Alkyl Radiotrifluoromethylation via Metallaphotoredox-Mediated Radical Cross-Coupling
Lukas Veth, Netherlands

PP39
Regulatory Challenges Using Novel Radionuclides in Radiopharmaceutical Development - PRISMAP's Activities Towards Harmonisation and Standardisation
Clemens Decristoforo, Austria

PP40
Optimisation of ⁸⁹Zr Production Using a Custom Liquid Target System For In Vivo Studies
Andrzej Czudek, Poland

PP41

In Vivo Pharmacokinetics of Novel ⁶⁸Ga-labeled pt(iv)-dfo Complexes in an Orthotopic Osteosarcoma Mouse Model

Ines Lopez Martinez, Austria

PP42

Optimization of [⁸⁹Zr] Zr-DOTA Radiolabeling: Balancing Zirconium Salt Stability and Chelation Efficiency.

Barthélémy Ramée, France

PP43

Development of a Freeze-Dried Daratumumab-Immunoconjugate for Lu-177 Radiopharmaceutical Preparation

Paulina Apostolova, North Macedonia

PP44

Radiolabeling and Biodistribution of HER2-Targeted ⁸⁹Zr-Labeled Magnetic Nanoparticle

Fatma Yurt, Türkiye

PP45

Impact of Radionuclide Nuclear Properties on the Dosimetric Outcome in Radioligand Therapy

Samuele De zan, Italy

PP46

Development and Synthesis of Theranostic ²²⁵Ac/La and ⁸⁹Zr/Zr Tracer Addressing the Somatostatin Receptor.

Nils Fabio Baier, Germany

PP47

Simplified, Mild Radiofluorination of a CEACAM5-targeting Nanobody Using Bioorthogonal Tetrazine Ligation

Jelena Saliën, Belgium

PP48

A Comparison of Cartridge-Based and Classical Methods of ¹⁸F-Radiofluorination of PET Tracers

Inês Farinha Antunes, Netherlands

PP49

Preclinical Assessment of a CCK2R-Targeted Minigastrin Analog for Radionuclide Therapy

Taraneh Sadat Zavvar, Austria

PP50

A Cassette-Based Process for the Multidose Production of [¹¹C]Acetate on the AllinOne

Laura Trump, Belgium

PP51

Separation of Radiometal-Labelled Peptides from Unlabelled Peptides by Hydrophilic Interaction Liquid Chromatography (HILIC)

Hiroyuki Suzuki, Japan

PP52

A New Fluorine-¹⁸ Radiolabelled Inhibitor of TRPC6 Receptor for PET Imaging of Glioblastoma.

Marco Iannone, Italy

PP53

How to Design New Processes for Direct and Indirect Radiofluorination?

Marine Steffann, France

PP54

Assessment of the Quality of ⁴⁷Sc Obtained Through Different Production Routes

Lucia De Dominicis, Italy

PP55

²-[¹⁸F]FDG μ PET/CT Reveals Whole-Body Metabolic Changes Upon Partial Hepatectomy in Mice

Eva-Maria Patronas, Austria

PP56

Monte Carlo Method for Evaluating ^{99m}Tc Organ Dosimetry: Advancing Optimized Use of Radiopharmaceuticals in Clinical Settings

Ali Alshehri, Saudi Arabia

PP57

Characterization of Binding Mechanism, Internalization and Excretion of ¹⁷⁷Lu-DOTATATE

Hadis Westin, Sweden

PP58

Synthesis of Fluorine-¹⁸ Labelled Radioligands for PET Imaging of GABA Transporter 1 (GAT1)

Niels Knippenberg, Netherlands

PP59

FAPI Tracer en Vogue: Evaluating [⁶⁸Ga]Ga-DATA5m.SA.FAPi for Molecular Imaging of Pulmonary Fibrosis

Victoria Weissenböck, Austria

PP60

Development and Evaluation of Two [^{99m}Tc]Tc tricarbonyl Complexes Derived from Laminin-111 for Molecular Imaging of the Tumor Microenvironment in Breast Cancer

Ana María Rey, Uruguay

PP61

Assessing DNA Damage, Cell-Cycle Progression and Proliferation in tp53 Wild-Type and Mutant Brain Tumour Cell Lines After AMG232 and Photon Irradiation

Musa Maluleka, South Africa

PP62

[¹⁸F]F-DBD-1/2: Novel Radiotracers Targeting the DNA Binding Domain of the Androgen Receptor.

Elmar Diekstra, Netherlands

PP63

Theranostic Potential of DOTAGA.Glu.(FAPI)₂ and DO3A.Glu.(FAPI)₂ with Human Dosimetry Extrapolation for their ¹⁷⁷-Lutetium and ¹⁶¹-Terbium Radiolabeled Analogues

Adrianna Bilinska, Switzerland

PP64

[^{99m}Tc]-TcRhBITC- Silk Fibroin Nanoparticles: a Dual Labeled Probe for Biomedical Applications

Nuria Olcina-Forner, Spain

PP65

Exploring the Theranostic Potential of [⁶⁴Cu]CuCl₂ in Advanced Patient-Derived Glioblastoma Models

Filipa Mendes, Portugal

PP66

Radiochemical and Biodistribution Profiles of ¹⁶¹Tb-HEDP and ¹⁶¹Tb-ZOL as Potential Agents for Bone-Targeted Radionuclide Therapy

Magdalena Radovic, Serbia

PP67

Development and Validation of [⁶⁸Ga]Ga-FAPI-46 Radiosynthesis Using a Galliad Generator and a miniAIO Synthesizer

Arnaud Deschavannes, France

PP69

Synthesis and Evaluation of a ⁶⁸Ga-Fab Radiotracer Directed Against CD133 for PET Imaging of Glioblastoma

Charlotte Collet, France

PP70

Preliminary Evaluation of ⁸⁹Zr-DFO-Fe₃O₄-mSi-Mn-Trastuzumab Nanoparticles for Dual PET/MR Imaging in Breast Cancer

Derya Özel, Türkiye

PP71

[123I]Italia: A PARP-Directed Auger Electron Emitting Agent for Targeted Radionuclide Therapy
Sreelakshmi Unnikrishnan, Netherlands

PP72

Verification of Heat Damaged Erythrocytes - Spherocytes Method Preparation
Aljaz Socan, Slovenia

PP73

PSMA-Targeted Gold Nanoparticles Radiolabeled with Lutetium-177 for Theranostic Applications in Prostate Cancer
Penelope Bouziotis, Greece

PP74

Investigating the Radiobiological Response of Combination of DNA Repair Inhibitors with a Suppression in Advanced Prostate Cancer
Ali Alshehri, Saudi Arabia

PP75

Post-Synthesis Complexation of Free Lu-177 in Peptide Radiolabeling via Secondary Heating Treatment
Mohammadreza Kamali Sarvestani, Germany

PP76

HOLD: Half-Life Optimization through Ligand-Derivatization: Prolonging the Biological Half-Life of Targeted Radioligands for Optimized Dosimetry
Patrick Arthur Cieslik, Germany

PP77

Evaluation of Different ¹⁷⁷Lu-Labeled Radiotracers Encapsulated Into Polymeric Nanoparticles: Does it Influence the Nanoparticle's Properties?
Nicolas Lepareur, France

PP78

Spheroids and Live Cells in Drug Development
Maria Winkvist, Sweden

PP79

The Development and Validation of an HPLC Method to Determine the Radiochemical Purity of FAPI-46 Labelled with Gallium-68, Lutetium-177 or Terbium-161
Elke van Brandwijk, Netherlands

PP80

From DOE-Optimized Radiolabeling to Full Automation: Robust Production of [¹⁸F]AIF-PSMA-11
Olga Ovdichuk, France

PP81

Feasibility of Preclinical SPECT Imaging of Actinium-225 via Its Decay Daughters
Theo Abel Spillum, Norway

PP82

Development of a GMP-Compliant Method for the Synthesis of [¹¹C]DASB
Dinzy Knuiman, Netherlands

PP83

Fully Automated Cassette-Based Radiosynthesis of [¹⁸F]AIF Octreotide on the AllinOne
Romaric Gerardy, Belgium

PP84

GMP Production of [¹⁸F]FE-PE2I on Trasis AllinOne Synthesis Module - PET Tracer for Imaging of the Dopamine Transport
Jin Han, Norway

PP85

Freeze-Dried Ready-to-use FAPI-04 Radiopharmaceuticals: Design and Radiolabeling with ¹⁷⁷Lu and ^{99m}Tc via HYNIC Chelation
Emilija Janevik-Ivanovska, North Macedonia

PP86

Strengthening Targeted Alpha Therapy in Widening Countries through NOAR Europe: Advancing Access and Infrastructure within EU Research and Innovation Frameworks
Emilija Janevik-Ivanovska, North Macedonia

PP87

Patterns of Diagnostic and Therapeutic Radiopharmaceutical Use in Slovenia, Greece and Cyprus: Results of IFIGENEIA Hospital Survey
Marko Kroselj, Slovenia

PP88

A Situational Analysis of Radiopharmaceutical Services in English-Speaking African Countries
Lerato Mosima, South Africa

PP89

From Radiochemistry to Biology: an Integrated Platform for in Vitro and in Vivo Preclinical Evaluation of Radiopharmaceuticals
Anna Gromotowicz-Poplawska, Poland

PP90

Public Short Survey on Radiotheranostic Landscape by Thera4care Ihi Project
Maria Rosaria Ruggiero, Italy

PP91

Customized Platform for Proposal & Project Management in a Experimental Radiopharmacy
Maria Rosaria Ruggiero, Italy

PP92

Preliminary Analysis of NHEJ DNA Repair Pathway Inhibitors in Breast Cancer Cell Lines
Dragos Andrei Niculae, Romania

PP93

Gallium-68 Radiolabelled PD-L1 Binding Peptide WL12 for Lung Cancer
Elif Tugce Sarcan Bozkir, Türkiye

PP94

Stability Assessment of ^{99m}Tc-Sestamibi under Various Storage Conditions
Magdalena Onuscakova, Czech Republic

PP95

Deviation Management as a Segment of Quality Assurance of PET Radiopharmaceuticals
Katerina Kolevska, North Macedonia


PP96

Determination of the Dead Time Factor of the radio-TLC scanner and Correction of Observed Count Rates for its Application in the Determination of Radiochemical Purity of ^{99m}Tc Radiopharmaceuticals
Marina Vivar Pérez, Spain

PP98

SuperOpTyMe: A Novel Radiopharmaceutical Approach for the Selective Detection of Multi-Resistant Bacterial Infections
Sofia Gama, Portugal

EXHIBITION PLAN



Venue Overview

Griegshallen
Edvard Griegs Plass 1
5015 Bergen, Norway
www.griegshallen.no/en

Registration Desk

1st floor - Foyer 1 Peer Gynt

Industry Exhibition

2nd floor – Foyer 2 Peer Gynt

Scientific Programme

2nd floor – Peer Gynt hall

LIST OF EXHIBITORS

Booth Number	Company
01	LabLogic Systems Limited
02	Triskem International
03	IRE ELiT
04	Von Gahlen
05	Ridgeview Instruments AB
06	RQS Alexander Ruffani
07	Trasis
08	Antec Scientific
09	Cyclomedica
10	Eichrom Technologies
11	BIOEMTECH
12	COMECER S.p.A
13	Jiangsu Huayi Radiopharmaceuticals Co., Ltd.
14	GE Healthcare Limited, UK
15	Nucare Inc.
16	IBA SA
17	Isotopia Molecular Imaging Ltd
18	Hidex Oy
19	Young Minds Lounge
20	Innovation Norway
21	Innovation Norway
22	Bruker BioSpin GmbH & Co. KG
23	JPT Peptide Technologies GmbH
24	Elysia-Raytest

PUBLISHER

AV ESRR
c/o EANM Executive Office

Schmalzhofgasse 26,
1060 Vienna, Austria
Phone: +43 1 890 44 27
Fax: +43 1 890 44 27-9
E-mail: esrr@esrr.info
Web: www.esrr.info

EDITOR

Petra Wurzinger,
Jessica Elenisse Filippi,
Alexander Berger
EANM Executive Office

LAYOUT & DESIGN

Olga Dogadina
EANM Executive Office

CONTENT

No responsibility will be taken by the EANM Executive Office regarding the correctness of the information provided.
Last updated in March 2026.

